Study of AZD2811 + Durvalumab in ES-SCLC

Running, not enrolling · Phase 2

Conditions studied: Small-Cell Lung Cancer

In brief

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Key facts

Study ID
NCT04745689
Run by
AstraZeneca
People needed
31
Starts
2021-02-23
Expected to finish
2026-12-01
Last updated by the study team
2026-07-06

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.